Encouraging results have been reported by recent studies showing that pancreatic carcinoma could be inhibited by controlling several biomarkers such as SMAD4, CXCR2, ABCG2 and Kras [28–34]. This evidence concerns the gene CXCR2 and exocrine pancreatic carcinoma.